Literature DB >> 1847844

Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.

Y Shimizu1, S Iwatsuki, R B Herberman, T L Whiteside.   

Abstract

Tumor-infiltrating lymphocytes (TIL) were isolated from 22 human primary and metastatic liver tumors, and expanded in vitro in the presence of either interleukin-2 (IL-2, 100 U/ml) plus tumor necrosis factor alpha (TNF alpha, 1000 U/ml), IL-2 (1000 U/ml) plus IL-4 (1000 U/ml) or IL-2 (1000 U/ml) alone. TIL proliferated in culture in 20/22 cases. Among different cytoline combination, TNF alpha and IL-2 were most effective in promoting the outgrowth of CD3+CD8+T lymphocytes (mean +/- SEM: 90% +/- 5) in the cultures of TIL from primary liver tumors. Cytotoxicity against autologous tumor cells was demonstrated in all early cultures of TIL from primary liver cancers in the presence of IL-2 plus TNF alpha. In contrast, cultures of TIL derived from colon cancer metastatic to liver had significantly lower levels of autotumor cytotoxicity and proportions of CD3+CD8+ cells (40% +/- 13) than those of TIL from primary liver tumors. The addition on day 0 of interferons (alpha or gamma) to TIL cultured in the presence of TNF alpha and IL-2, significantly augmented cytotoxicity against autologous tumor. In contrast, incubation of TIL in the presence of IL-4 and IL-2 did not result in increased autotumor responses in the cultures of TIL from primary liver tumors. The expansion (-fold) of TIL (day 30) cultured in the presence of IL-2 alone compared to that in the presence of TNF alpha and IL-2 was significantly greater for hepatocellular carcinoma (median, 280 vs 260) than for autologous peripheral blood lymphocytes (36 vs 27), cholangiocarcinoma (42 vs 51) or TIL from metastatic colon cancer (39 vs 30). Outgrowth of TIL in IL-2 plus TNF alpha offers an opportunity for in vitro enrichment in cells with autotumor cytotoxicity in primary liver tumors. However, this cytokine combination was unable to promote and sustain growth of autotumor effectors from TIL in metastatic liver cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847844     DOI: 10.1007/bf01789045

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

1.  Monoclonal antibodies to interferon-gamma inhibit interleukin 2-dependent induction of growth and maturation in lectin/antigen-reactive cytolytic T lymphocyte precursors.

Authors:  M M Simon; U Hochgeschwender; U Brugger; S Landolfo
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

2.  Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.

Authors:  Y L Wang; L S Si; A Kanbour; R B Herberman; T L Whiteside
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

3.  Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors.

Authors:  Y Shimizu; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

4.  Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors.

Authors:  S Miescher; M Stoeck; L Qiao; C Barras; L Barrelet; V von Fliedner
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; S L Schwarz; P J Spiess
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

6.  Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

Authors:  R B Cameron; J K McIntosh; S A Rosenberg
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

7.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

Authors:  P J Spiess; J C Yang; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

8.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes.

Authors:  G Trenn; H Takayama; J Hu-Li; W E Paul; M V Sitkovsky
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  14 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 2.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

3.  Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.

Authors:  Simon Turcotte; Alena Gros; Katherine Hogan; Eric Tran; Christian S Hinrichs; John R Wunderlich; Mark E Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

4.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

5.  Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells.

Authors:  M Lindauer; H K Schackert; J Gebert; W Rudy; A Habicht; M Siebels; S C Meuer; U Moebius
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

6.  Antibodies to tumor necrosis factor: a component of B cell immune responses with a role in tumor/host interaction.

Authors:  J A Barbuto; W J Grimes; E M Hersh
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

7.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

8.  Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion.

Authors:  S S Hom; S A Rosenberg; S L Topalian
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.

Authors:  L Rivoltini; F Arienti; A Orazi; G Cefalo; M Gasparini; C Gambacorti-Passerini; F Fossati-Bellani; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; A Milani; E Pirone; D Nitti; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.